Glossary | Articles/Abstracts | Curricula Vitae | Additional Resources
Curricula Vitae
Peter D. Grimm, D.O.
Executive Director – (July 2009-present) – Prostate Cancer Center of Seattle
Chief Executive Officer – ProQura, LLC
CURRICULUM VITAE
PETER D. GRIMM, D.O.
Prostate Cancer Center of Seattle
9730 3rd Ave NE, Suite 208
Seattle, WA98115
Wk: 206-453-2992 Fx: 206-525-5321
Email: Peter@Grimm.com
CURRENT STATUS
Executive Director Prostate Cancer Center of Seattle
July 2009-present
Chief Executive Officer: ProQura, LLC
2001-present
PREVIOUS POSITIONS
Director of Business Operations Seattle Prostate Institute
2008-2008
Director of Clinical Research Seattle Prostate Institute
2005-2008
Medical Director Seattle Prostate Institute
1997-2005
Radiation Oncologist: Tumor Institute Group of Seattle
1985-2009
EDUCATION
Undergraduate: 1970-1974 Seattle University, Seattle, WA (Cum Laude)
MedicalSchool: 1975-1979 Midwestern University (ChicagoCollege of Osteopathic Medicine),
Chicago, IL
Internship: 1979-1980 Eastmoreland General Hospital, Portland, OR
Residency: 1980-1983 UCLA Dept of Radiation Oncology (Robert Parker, M.D.)
1982-1983 Chief Resident UCLA Department of Radiation Oncology
LICENSURE / CERTIFICATION
Board Status: Board Certified – AmericanCollege of Radiology-Therapeutics 06/84
Licensure: WashingtonState 1984, California 2009, Florida 2009, Alaska 2009
PROFESSIONAL SOCIETIES
Member: Medicare Practicing Physician Advisory Council 2004-2008
American Society Therapeutic Radiation Oncology Economic Committee
Southwest Oncology Group
National Cancer Institute
Practicing Physicians Advisory Council
King County Medical Society
American Society for Therapeutic Radiology and Oncology
Washington Osteopathic Medical Association
Puget Sound Oncology Consortium
WashingtonState Radiological Society (Past President)
American Brachytherapy Society
Board Member: Long Live the Kings
Pacific NorthwestUniversity of Health Sciences
Advisory Boards: Oncura, Inc
Bard, Inc
Nexcura, Inc
AWARDS / FELLOWSHIPS
June, 1979 Who’s Who, AmericanColleges and Universities
June, 1980 Outstanding Senior-Emergency Medicine, ChicagoCollege of Osteopathic Medicine
July, 1982-June, 1983 American Cancer Society Fellowship, UCLA
November ,2009 President’s Award American Brachytherapy Society
March, 2012 Heatherington Lifetime Achievement Award, Northwest Osteopathic Medical Foundation
FACULTY APPOINTMENTS
1983-1984 Adjunct Assistant Professor of Radiation Oncology, UCLA Dept. of Radiation Oncology
1986-2001 Clinical Professor, College of Medicine of the Pacific
UNITED STATES PATENTS
Current: US Patent No. 5,938,583 – Precision implant needle and method of using same in seed implant treatment of prostate cancer. Granted August 17, 1999.
US Patent No. 6,027,446- No pubic arch detection and interference assessment in transrectal ultrasound guided prostate cancer therapy. Granted February 22, 2000.
US Patent No. 6,010, 446- Spacer element for joining radioactive seeds used in treatment of cancer. Granted September 17, 2002.
US Patent No. 6,450,939- Hinged spacer element for joining radioactive seeds used in treatment of cancer. Granted September 17, 2002.
US Patent No. 6,264,600- Hollow suture member with radioactive seeds positioned therein for treatment of prostate cancer. Granted July 24, 2001.
US Patent No. 6,402,695- Cover for ultrasound probe. Granted June 11, 2002.
SELECTED PRESENTATIONS
01/04/2001 “Recent Advances in Prostate Cancer” Medical Education Collaborative Las Vegas, NV
01/20/2001 “Overview of Brachytherapy for Prostate Cancer; The Seattle Experience” 3rd Annual Prostate Brachytherapy, Seminar Lynn Regional Cancer Center, Boca Raton, FL
01/27/2001 “Radiation Therapy in the Patient With Prostate Cancer: Current Strategies” Issues in Advanced Prostate Cancer, MPE Communications, Phoenix, AZ
3/31/2001 Radiation Oncology Advisory Board, Amgen and Praecis, Lake Tahoe, NV
4/6/2001 “Advance in Brachytherapy” Recent Advances in Prostate Cancer-Medical Education Collaborative, Pittsburgh, PA
4/19/2001 “Defining the Ideal Candidate: Seed Implant” 4th Annual Advanced Prostate Brachytherapy Conference, SeattleWA
4/19/2001 “Defining the Ideal Candidate: PSA Endpoints” 4th Annual Advanced Prostate Brachytherapy Conference, SeattleWA
4/20/2001 “Complication Management: Quality Assurance” 4th Annual Advanced Prostate Brachytherapy Conference, SeattleWA
5/18/2001 “Prostate Brachytherapy” Grand Rounds, RobertH.LurieCancerCenter Northwestern University, Chicago, IL
4/12/2002 “Implant Alone vs. Combined Therapy for Intermediate Prostate Cancer” 5th Annual Advanced Prostate Brachytherapy Conference, SeattleWA
5/3/2002 “Recent Advances in the Management of Prostate Cancer” ICPME, Pittsburgh, PA
10/10/2002 “Modern Prostate Brachytherapy” Boston Urologic Society, Boston, MA
4/4/2003 “Recent Advances in the Management of Prostate Cancer”, ICPME, Austin, TX
4/11/2003 “Seed Migration: Strands vs. Loose Seeds” 6th Annual Advanced Prostate Brachytherapy Conference, SeattleWA
5/14/2003 “Prostate Brachytherapy Update” San Jose Prostate Cancer Support Group, San Jose, CA
9/12/2003 Swedish Medical Center-YPO Meeting, Seattle, WA
9/13/2003 Amersham Meeting, Chicago, IL
10/22/2003 SarahCannonCancerCenter, Chattanooga, TN
10/23/2003 Trident Cancer Center, Charleston, SC
12/2/2003 Spectrum Health, Grand Rapids, MI
1/23/2004 Bard Corporate National Sales Meeting, Phoenix, AZ
3/5-6/2004 Boca RatonCommunityHospital, Boca Raton, FL
3/10/2004 Oncura Advisory Board Meeting, New York, NY
3/13/2004 North American Scientific Meeting, Syracuse, NY
4/16/2004 91st Annual Scientific Meeting-Texas Radiological Society Irving, TX,
5/7/2004 3rd Annual Perspectives in Genitourinary Cancer Care San Francisco
5/13-15/2004 ESTRO Barcelona, Spain
5/17/2004 Medicare- Practicing Physician Advisory Council, WashingtonDC
6/25/2004 91st Annual Northwest Osteopathic Convention (WOMA), Blaine, WA
8/25-27/2004 SMC_MIYMSA Meeting Guadalajara, Mexico
8/30/2004 Medicare- Practicing Physician Advisory Council, WashingtonDC
9/14/2004 FoothillsHospital Meeting, Calgary, Canada
9/30/2004 Hamilton Medical Center-CME on Prostate Brachytherapy, Dalton, GA
10/4/2004 ASTRO-Poster Presentation Atlanta, GA
11/9/2004 WOMA “Is It Prostate Cancer or Benign Prostatic Hyperplasia?” Seattle, WA
11/18/2004 Mexican Urologic Association SMU Congress, Merida, Mexico
11/22/2004 Medicare- Practicing Physician Advisory Council, WashingtonDC
12/10/2004 Watson Advisory Board
5/3-5/2008 World Congress of Brachytherapy Annual Meeting Poster Presentation Boston, MA
04/17/2009 One to 3 lectures every year at the Seattle Prostate Institute Annual Advanced Prostate
Brachytherapy Conference from 1997 through 2009
5/31/2009 American Brachytherapy Society 2009 Annual Meeting Poster Presentation, Toronto, CA
3/5/2010 American Society of Clinical Oncology San Francisco 15 Year Brachytherapy Results
and Comparative Effectiveness presentations.
02/2011 Sun, Sands, and Seed Prostate Conference, Boca Raton, Florida “Long Term Outcomes
with Brachytherapy for Prostate Cancer”
5/10-12/2011 The Inaugural International Prostate Cancer Symposium, Weill Cornell Medical College,
New York, NY: Chair & Presenter “Outcomes After Brachytherapy”
9/11-12/2011 Oncura Focal Therapy Meeting, The United Kingdom
12/3-4/2011 Quality Assurance in Prostate Brachytherapy, Univ. Texas, MD Anderson Cancer Center,
Houston, TX: Presenter “What has the VA taught us about the process of QA in
Brachytherapy” & Comparative Effectiveness”
2/22-25/2012 SRS/SBRT Scientific Meeting, the La Costa Resort and Spa, Carlsbad, CA: Panelist-
“Early Stage Prostate Cancer: SRS, Brachytherapy, IMRT & Surgery”
3/9-10/2012 Sun, Sand, & Seeds Conference, Boca- Raton, FL: New Frontiers in Prostate Cancer with
a Session on Proton Therapy: Presenter
3/23-24/2012 Prostate Brachytherapy UK and Ireland Conference 2012, St. James Institute of Oncology,
The Royal Armouries in Leeds, West Yorkshire, UK: Speaker
6/21-24/2012 99th Annual Northwest Osteopathic Convention, Pacific Northwest University of Health
Sciences, Semiahmoo Hotel & Conference Center, Blain, WA
9/14/2012 Interview with NPR on Proton Therapy
9/14/2012 Interview with Reader’s Digest on PCRSG study results
9/18/2012 Presentation with US TOO on “New Developments in Prostate Cancer”
PUBLICATIONS
- Hawkins RA, Phelps ME, Huang SC, Wapenski IA, Grimm PD. “A kinetic Evaluation of Blood Brain Barrier Permeability in Human Brain Tumors,” Journal of Cerebral Blood Flow, December 1984.
- Ragde H, Blasko JC, Schumacher D, Grimm PD. “Treatment of Localized Prostate Carcinoma with Iodine-125 Seeds Percutaneously Placed Under Ultrasound and Template Guidance,” Endosonographique, 1988.
- Parker RP, Grimm PD; “Bilateral Breast Cancer,” Journal of Clinical Oncology, June 1989.
- Ragde H, Blasko JC, Schumacher D, Grimm PD, Sylvester JE, Mate TP. “Use of Transrectal Ultrasound In Transperineal I-125 Seeding for Prostate Cancer,” J. Endourology.
- Blasko JC, Ragde H, Grimm PD. “Transperineal Ultrasound Guided Implantation of the Prostate: Morbidity and Complications,” Scand J. Urol. Nephroll, 137:87-92, 1991.
- Blasko JC, Grimm PD, Ragde H. “Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate,” Seminars in Radiation Oncology.3:240-249, 1993.
- Grimm PD, Blasko JC, Ragde H. “Ultrasound Guided Transperineal Implantation of I-125 and Palladium-103 for the Treatment of Early Stage Prostate Cancer: Technical Concepts in Planning, Operative Technique and Evaluation,” Urologic Clinics North America, November, 1994.
- Porter AT, Blasko JC, Grimm PD, Reddy SM, Ragde H. “Brachytherapy For Prostate Cancer,” CA Cancer Journal for Clinicians, Vol. 45, pp. 165-178, 1995.
- Blasko JC, Wallner K, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Cavanagh W, Landin K. “Prostate Specific Antigen Based Disease Control Following Ultrasound Guided 125-Iodine Implantation For Stage T1/T2 Prostatic Carcinoma,” Journal of Urology, Vol. 145, pp. 1096-1099, 1995.
- Grimm PD, Blasko JC, Ragde H, Cavanaugh W, Sylvester JE. “Does Brachytherapy have a Role in early Stage Prostate Cancer,” Hematology Oncology Clinics of North America, June 1996.
- Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanaugh W, Grimm PD. “Should Brachytherapy be Considered a Therapeutic Option in Localized Prostate Cancer,” Urologic Clinics of North America, Vol. 23, pp. 633-650, 1996.
- Luse RW, Blasko JC, Grimm PD. “A Method for Implementing the American Association of Physicists in Medicine Task Group-43 Dosimetry Recommendations for 125 I Transperineal Prostate Seed Implants on Commercial Treatment Planning Systems,” Int. Journal Radiation Oncology, Biology and Physics, Vol. 37 (3), pp. 737-741, 1997
- Nag S, Baird M, Blasko JC, Beyer D, Dattoli M, Grado G, Grimm PD, et all. “American Brachytherapy Society Survey of Current Clinical Practice For Permanent Brachytherapy of Prostate Cancer,” Journal of Brachytherapy Int., Vol. 35, pp. 243-251, July 1997.
- Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K, Cavanagh W. “Interstitial Iosine-125 Radiation Without Adjuvant Therapy in the Treatment of Clinically Localized Prostate Carcinoma,” Cancer, Volume 80, No. 3, pp. 442-453, August 1997
- Blasko JC, Ragde H, Grimm PD, Sylvester J, Cavanagh W. “Potential for Neoadjuvant Hormonal Therapy with Brachytherapy for Prostate Cancer,” Molecular Urology 1 (2), pp. 207-214, 1997.
- Nag S, Baird M, Blasko JC, Beyer D, Dattoli M, Grado G, Grimm PD et al. “American Brachytherapy Society Survey of Current Clinical Practice for Permanent Brachytherapy of Prostate Cancer,” Journal of Brachytherapy International, Vol.13, pp. 243-251, 1997
- Sylvester J, Blasko JC, Grimm PD, Ragde H. “Interstitial Implantation Techniques in Prostate Cancer,” Journal of Surgical Oncology, Vol. 66, pp. 65-75 1997.
- Blasko JC, Grimm PD, Ragde H, Schumacher D. “Implant Therapy for Prostate Cancer. Urologic Cancer,” Blackwell Science, p. 137-155, 1997.
- Grimm PD, Blasko JC, Ragde H, Cavanaugh B. “Transperineal I-125 Pd 103 Brachytherapy for Early Stage Prostate Cancer,” ASTRO abstract, 1997
- Blasko JC, Grimm PD, Ragde H. “Neoadjuvant Total Androgen Blockade and Combined External Beam Irradiation Brachytherapy Boost for Locally Extensive Prostate Cancer: Gland Downsizing and Early Clinical Results,” Abstract. 1997.
- Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, HoakDC, Cavanagh W, Landin K. “Brachytherapy For Clinically Localized Prostate Cancer: Results at 7 and 8 Year Follow-up,” Seminars in Surgical Oncology, Vol. 13, pp. 438-443, 1997.
- Prestidge BR, Prete JJ, Buchholz TA, Friedland JL, Stock RG, Grimm PD, Bice WS. “A Survey of Current Clinical Practice of Permanent Prostate Brachytherapy in The United States,” Int. J. Oncology, Biology & Physics, Vol. 40, No 2, pp. 461-465, 1998.
- Tapen E, Blasko J, Grimm P, Radge H, Luse R, Clifford S, Sylvester J, Griffin T. “Reduction of Radioactive Seed Embolization to the Lung Following Prostate Brachytherapy,” International Journal of Radiation Oncology, Biology and Physics, Vol 42, No. 5, pp. 1063-1067, 1998.
- S. Vermeulen, R. Young, A. Posewitz, P. Grimm, J. Blasko, E. Kohler, J. Raisis. “Stereotactic Radiosurgery Toxicity In Treatment of Intracanalicular Acoustic Neuromas: The Seattle Northwest Gamma Knife Experience,” Stereotactic and Functional Neurosurgery, Vol. 70(suppl 1), pp. 80-87, 1998.
- Prete JJ, Prestidge BR, Bice WS, Friedland JL, Stock RG, Grimm PD. “A Survey of Physics and Dosimetry Practice of Permanent Prostate Brachytherapy in The United States,” Int. J. Radiation Oncology, Biology & Physics, Vol. 40, No 4, pp. 1001-1005, 1998
- S. Pathak, P. Grimm, V. Chalana, Y Kim. “Pubic Arch Detection in Transrectal Ultrasound Guided Prostate Cancer Therapy,” IEEE Transactions on Medical Imaging, Vol. 17, No. 5. October 1998.
- Naig S, Beyer D,. Friedland D’ Grimm PD, Nath D. “American Brachytherapy Society (ABS) Recommendations for Transperineal Permanent Brachytherapy of Prostate Cancer,” Int. J. Radiation Oncology, Biology Physics, Vol. 44, No. 4, pp. 789-799, February 1999.
- Merrick GS, Butler WM, Grimm PD. “Prostate Specific Antigen Levels After Radical Prostatectomy Versus Brachytherapy,” Urology, Vol. 53, pp. 865-866, 1999.
- CW, Blasko JC, Grimm PD, Sylvester JE. “Transient Elevation of Serum Prostate-Specific Antigen Following 125I/103Pd Brachytherapy for Localized Prostate Cancer,” Seminars in Urologic Oncology, Vol. 18, No 2, pp. 160-165, May 2000.
- Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. “The Role of External Beam Radiotherapy With I-125/Pd-103 Brachytherapy For Prostate Carcinoma,” Radiotherapy and Oncology: Journal of The European Society For Therapeutic Radiology and Oncology, Vol. 57, pp. 273-278, 2000.
- Sylvester JE, Blasko JC, Grimm PD, Meier R, Cavanagh W. “Short Course Androgen Ablation Combined With External Beam Radiation Therapy And Low Dose Rate Permanent Brachytherapy in Early Stage Prostate Cancer: A Matched Subset Analysis,” Molecular Urology, Vol. 4, pp. 155-159, 2000.
- Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. “Palladium 103 Brachytherapy For Prostate Carcinoma,” Int. Journal Radiation Oncology, Biology and Physics, Vol. 46, pp. 839-850, 2000.
- Sylvester JE, Grimm PD, Blasko JC, Meier R, Spiegel J, Heaney C, Cavanagh W. “The Role of Androgen Ablation in Patients With Biochemical of Local Failure After Definitive Radiation Therapy: A survey of Practice Patterns of Urologists and Radiation Oncologists in The United States,” Urology, Supplement 2A, pp. 65-70, August 2001.
- Grimm PG, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. “10-Year Biochemical (Prostate-Specific Antigen) Control of Prostate Cancer With 125I Brachytherapy”, International Journal of Radiation Oncology Biology, Vol. 51, No. 1, pp. 31-40, 2001.
- Grimm PD, Sylvester JE. “Permanent Seed Brachytherapy in Patients With Advanced Prostate Cancer: Current Strategies,” Advances in Prostate Cancer, Vol. 5, No. 2, June 2001.
- Grimm, PD, Blasko JC, Sylvester JE. “Clinical Selection Issues for Permanent Seed Prostate Brachytherapy” J. of Brachytherapy International, Vol. 16, No. 2, pp. 143-152, July-September 2001
- Sylvester JE, Blasko JC, Grimm PD, Meier R, Heaney C, Cavanagh W. “Impact of Short-Course Androgen Ablation on the Biochemical Progression-Free Survival of High-Risk Prostate Cancer Patients Managed With Permanent Brachytherapy,” J. of Brachytherapy International, Vol. 16, No. 2, pp. 173-180, July-September 2001
- Sylvester JE, Blasko JC, Grimm PD, Meier R. “Transperineal Permanent Brachytherapy for Local Recurrence Following External Beam Radiation for Early Stage Prostate Cancer,” J. of Brachytherapy International, Vol. 16, No. 2, pp. 181-188, July-September 2001
- Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. “10-Year Biochemical (Prostate-Specific Antigen) Control Of Prostate Cancer With 125I Brachytherapy,” Int. Journal of Radiation Oncology Biology & Physics, Vol. 51, No. 1, pp. 31-40, 2001
- Sylvester JE, Blasko JC, Grimm PD. Brachytherapy as Monotherapy, In Prostate Cancer Principles & Practice, Koss, Isaacs & Scher (eds.), Lippincott, Williams & Wilkins, Philadelphia, PA, pp. 336-357, 2002
- Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. “Brachytherapy for Carcinoma of the Prostate: Techniques, Patient Selection, and Clinical Outcomes,” Seminars in Radiation Oncology, Vol. 12, No 1, pp. 81-94, January 2002
- Bagley Jr CM, Lane RF, Blasko JC, Grimm PD, Ragde H, Cobb OE, Rowbotham RK. “Adjuvant Chemohormonal Therapy of High Risk Prostate Carcinoma Ten Year Results,” Cancer, Vol 94, No. 10, pp. 2728-2732, May 2002
- Sylvester JE, Blasko JC, Grimm PD. “Transrectal Ultrasound-Guided Prostate Brachytherapy. Image Guided Diagnosis and Treatment of Cancer, 1st ed, D’Amico A, Loeffler J, and Harris J Editors, Towowa, NJ: Humana Press, pp.119-154, 2003.
- Smith S, Wallner K, Merrick G, Butler W, Sutlief S, Grimm P. “Interpretation of pre- versus postimplant TRUS images.” Medical Physics 30(5): 920-24, June 2003.
- Grimm PD, Sylvester JE, Blasko JC, et al. Prostate Seed Implantation for Prostate Cancer. PCR Insights 6(4): 1-9, 12-13, November 2003
- Grimm PG, Blasko JC, Sylvester JE. The Prostate Cancer Treatment Book. New York: McGraw-Hill. 2004
- Sylvester JE, Blasko JC, Grimm PD, et al. “Fifteen Year Follow up of The First Cohort of Localized Prostate Cancer Patients Treated With Brachytherapy”, Journal of Clinical Oncology, 22:14S:4567, 2004
- Grimm PG, Blasko JC, Sylvester JE, et al. “Technical Improvement in Permanent Seed Implantation: A 2-Stage Brachytherapy System: Description and Comparison with Current Technique”, Brachytherapy Vol. 3, No. 1, pp.34-40, May 2004
- Grimm, P and Sylvester, J. “Advances in Brachytherapy.” Rev in Urology 6(Supp. 4), S37-48, Feb. 2004.
- Grimm PD, Ryan RA, Stern EM, Belland A, Page JA, Barrett P. “The effect of Income on Prostate Cancer Patient’s Awareness and Discussion Levels of Treatment Options.” Abstract. American Society for Therapeutic Radiology and Oncology 46th Annual Meeting, Atlanta, GA October 2004
- Sylvester JE, Blasko JC, Grimm PD, et al. “Fifteen Year Outcomes of Prostate Cancer Patients Treated With Brachytherapy”; BJU abstract 2005.
- Merrick GS, Butler WM, Wallner KE, Blasko JC, Michalski J, Aronowitz J, Grimm P, Moran BJ, McLaughlin PW, Usher J, Lief JH, Allen ZA. “Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.” Brachytherapy 4(4), 241-51, Jan 2005.
- Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD. “Second Malignancies After Prostate Brachytherapy: Incidence of Bladder and Colorectal Cancers in Patients with Fifteen Years of Potential Follow-up”; International Journal of Radiation Oncology Biology Physics 2006;66:3:669-673.
- Sylvester JE, Grimm PG, Blasko JC, Millar J, Orio III PF, Skoglund S, Galbreath RW, Merrick G. “15-Year Biochemical Relapse Free Survival in Clinical Stage T1-T3 Prostate Cancer Following Combined External Beam Radiotherapy and Brachytherapy; Seattle Experience”; International Journal of Radiation Oncology Biology Physics 2007;67:1:57-64.
- Merrick GS, Grimm PD, Sylvester J, Blasko JC, et al. “Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry,” Brachytherapy 2007; 6(1):9-15.
- Steven J. Frank, Peter D. Grimm, John E. Sylvester, Gregory S. Merrick, et al. “Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in theUnited States,” Brachytherapy 2007; 6(1):2-8.
- John Sylvester, Tricia Zeller, Chris J. Hennessy, Steve Eulau, Peter Grimm. Overview of the Calypso® 4D Localization System™; American College of Radiation Oncology Practice Management Guide, American College of Radiation Oncology, Bethesda, MD 2008.
- John Sylvester, Gregory S. Merrick, Peter Grimm, et al: “Influence of Pro-Qura Feedback on Rectal Dosimetry Following Permanent Prostate Brachytherapy,” 2008 World Congress of Brachytherapy, May 3-6, 2008. Brachytherapy, Vol. 7, No. 2, pp. 121, April-June 2008.
- C. Louiselle, G.S. Merrick, J. Sylvester, P. Grimm, S. Eulau, M. Waheed, Z.A. Allen, W.M. Butler. “Analysis of the Pro-Qura Database: Implant Quality, Brachytherapist Experience and Rectal Dose Parameters,” ASTRO 50th Annual Meeting, Boston, MA, September 21-25, 2008. International Journal of Radiation Oncology Biology Physics; 72: (1): S326.
- Robert K. Takamiya, Timothy P. Mate, John E. Sylvester, Stephen M. Eulau, Peter D. Grimm. “Clinical Experience with Calypso-Guided EBRT Following Seed Implantation,” 2008 World Congress of Brachytherapy, May 3-6, 2008. Brachytherapy, Vol. 7, No. 2, pp. 179, April-June 2008.
- John Sylvester, Peter D. Grimm, Stephen M. Eulua, Robert K. Takamiya, Devi Naidoo. “Permanent Prostate Brachytherapy Preplanned technique: The modern Seattle Method Step by Step and Dosimetric Outcomes,” 2008 World Congress of Brachytherapy, May 3-6, 2008. Brachytherapy, Vol. 7, No. 2, April-June 2008.
- Allen Z, Merrick GS, Grimm P, Blasko J, Sylvester J, Butler W, Chaudry UU, Sitter M. “Influence of Pro-Qura-Generated Plans on Postimplant Dosimetric Quality: A Review of a Multi-Institutional Database,” Medical Dosimetry, 2008 Autumn; 33(3):206-14.
- Allen Z, Merrick GS, Grimm P, Blasko J, Sylvester J, Butler W, Chaudry UU, Sitter M. “Influence of Pro-Qura-Generated Plans on Postimplant Dosimetric Quality: A Review of a Multi-Institutional Database,” Medical Dosimetry, 2008 Autumn; 33(3):206-14.
- Orio PF 3rd, Merrick GS, Grimm P, Blasko J, Sylvester J, Allen ZA, Butler WM, Chaudhry UU. “Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of Pro-Qura database,” Am J Clin Oncology 2008 Dec 31(6):523-31.
- Sylvester JE, Grimm PD, Eulau SM, et al. “Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes,” Brachytherapy 2009 Apr-Jun;8(2):197-206.
- John E. Sylvester, Jason Wong, Erik Torgerson, Jonathan Khanjian, Peter Grimm. “Randomized trial comparing intra-operative flexible, rigid and no cystoscopy after prostate brachytherapy,” Brachytherapy abstract, Vol. 8, No. 2, pp. 168, May 30-June 2, 2009.
- John E. Sylvester, Peter D. Grimm, Jason Wong, et al. “Prostate brachytherapy biochemical relapse free survival outcomes in intermediate risk prostate cancer patients,” Brachytherapy abstract, Vol. 8, No. 2, pp. 140, May 30-June 2, 2009.
- John E. Sylvester M.D., Peter D. Grimm D.O., Jason Wong M.D., et al. “15 year Biochemical Relapse-Free Survival following I125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience,” accepted for publication and presentation at the 51st American Society for Radiation Oncology Annual Meeting, abstract, Chicago, IL, November 1-5, 2009.
- Jason Wong M.D., John E. Sylvester M.D., Peter D. Grimm D.O., et al. “First report on the use of a thinner I125 radioactive seed that fits into 20 gauge needles for permanent seed prostate brachytherapy: A report on post-implant dosimetry and acute toxicity,” accepted for publication and presentation at the Canadian Association of Radiation Oncologists Annual Meeting, abstract, Toronto, CA, November, 2009.
- Jason Wong M.D., John E. Sylvester M.D., Peter D. Grimm D.O., et al. “First report on the use of a thinner I125 radioactive seed that fits into 20 gauge needles for permanent seed prostate brachytherapy: A report on post-implant dosimetry and acute toxicity,” accepted for publication and presentation at the 51st American Society for Radiation Oncology Annual Meeting, abstract, Chicago, IL, November 1-5, 2009.
- Merrick, G. Sylvester, J. Grimm, P. Allen ,Z. Butler,W. Reed,J. Khanjian,J. “Post implant rectal dosimetry is not dependent on Pd 103 or I-125 seed activity.” Brachytherapy, 10:35-43, 2010.
- Merrick GS, Lief JH, Grimm P, Sylvester J, Butler WM, Allen ZA. “The effect of pro-qura case volume on post-implant prostate dosimetry.” IJROBP 81(5): e727-34, 2011.
- Frank SJ, Levy LB, van Vulpen M, Crook J, Sylvester J, Grimm P, Pugh TJ, Swanson DA. “Outcomes after prostate brachytherapy are even better than predicted.” Cancer 118(3):839-47, 2011.
- Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC. “Fifteen Year bio-chemical relapse-free survival, cause specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prosate cancer: Seattle experience.” IJROBP 2011, 81(2): 376-81.
- Buyyounouski, M. Davis, B. Prestidge, B. Shanahan, T. Stock, R. Grimm, P. Demanes, J. Zaider, M. Horwitz, E. “A Survey of Current Clinical Practice in Permanent and Temporary Prostate Brachytherapy: 2010 Update.” Brachytherapy, 2012, Feb. 11 (Epub ahead of print.)
- Peter Grimm, Ignace Billiet, David Bostwick, Adam P. Dicker, Steven Frank, Jos Immerzeel, Mira Keyes, Patrick Kupelian, W. Robert Lee, Stefan Machtens, Jyoti Mayadev, Brian J. Moran, Gregory Merrick, Jeremy Millar, Mack Roach, Richard Stock, Katsuto Shinohara, Mark Scholz, Ed Weber, Anthony Zietman, Michael Zelefsky, Jason Wong, Stacy Wentworth, Robyn Vera, Stephen Langley. “Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group” BJU Int. 2012, 109(Suppl 1), 22-29.